Company / Working Capital
Annovis Bio, Inc. Working Capital History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$5.9M
FY2023
5-year range
$5.9M / $44.5M
FY2020-FY2023
Trend
-79.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $44M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2023 with a 3-year CAGR of -7.7%.
Declined from $44M to $6M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -7.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -7.7%, indicating a declining trend.
- In FY2023, working capital decreased 79.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $5.9M | -79.1% |
| FY2022 | $28.3M | -36.3% |
| FY2021 | $44.5M | +490.0% |
| FY2020 | $7.5M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026